Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13398
Abstract: Parathyroid carcinoma (PC) is an ultra-rare malignancy with a high risk of recurrence after surgery. Tumor-directed systemic treatments for PC are not established. We used whole-genome and RNA sequencing in four patients with advanced PC… read more here.
Keywords: targeted therapy; advanced parathyroid; parathyroid carcinoma; therapy advanced ... See more keywords
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5787
Abstract: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect… read more here.
Keywords: plus tyrosine; kinase inhibitor; immunotherapy plus; tyrosine kinase ... See more keywords
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00760-0
Abstract: SummaryThe second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab,… read more here.
Keywords: advanced hcc; therapy advanced; therapy; line therapy ... See more keywords
Molecular-Driven Therapy in Advanced Thyroid Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-021-00822-7
Abstract: With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or… read more here.
Keywords: thyroid cancer; molecular driven; therapy advanced; driven therapy ... See more keywords
Pembrolizumab vs chemotherapy as 2L therapy for advanced esophageal cancer: Japanese Subgroup Analysis in KEYNOTE-181
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz339.026
Abstract: Abstract Background Safe and effective treatment of advanced esophageal cancer is an area of unmet need. KEYNOTE-181 is a global, randomized, open-label, phase 3 study of pembrolizumab (PBR) vs chemotherapy (SoC) as second-line therapy for… read more here.
Keywords: esophageal cancer; keynote 181; therapy advanced; advanced esophageal ... See more keywords
Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC)
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2018-225048
Abstract: We describe a 73-year-old man who developed adrenal insufficiency 7 months after completing nivolumab therapy for advanced non-small cell lung cancer. He presented with non-specific symptoms of malaise and fatigue with an insidious 13.6 kilogram weight… read more here.
Keywords: advanced non; nivolumab therapy; therapy advanced; non small ... See more keywords
PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620720914490
Abstract: Recent results of randomized phase III studies of FDG-PET-adapted therapy for advanced Hodgkin lymphoma (HL) have clearly demonstrated benefit to alteration of treatment according to interim response, in particular regarding reducing toxicity while maintaining efficacy.… read more here.
Keywords: advanced hodgkin; therapy advanced; pet adapted; hodgkin lymphoma ... See more keywords
Neoadjuvant therapy in advanced melanoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21555
Abstract: e21555Background: Treatment paradigms in advanced melanoma are evolving with the success of new targeted and immunotherapies. The purpose of this study is to explore the outcomes associated with ne... read more here.
Keywords: oncology; advanced melanoma; therapy advanced; neoadjuvant therapy ... See more keywords
Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.533
Abstract: 533Background: Sorafenib or lenvatinib are the current frontline options for advanced HCC. Multiple biologic agents including multi-Tyrosine Kinase Inhibitors (TKI) cabozantinib & regorafenib have ... read more here.
Keywords: biologics second; immunotherapy versus; therapy advanced; versus biologics ... See more keywords
Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the Endocrine Society"
DOI: 10.1210/js.2018-00180
Abstract: Abstract Thyroid cancer, with the exception of anaplastic thyroid cancer, typically has very favorable outcomes with the standard therapy. However, those that persist, recur, or metastasize are associated with a worse prognosis. Targeted therapy with… read more here.
Keywords: systemic therapy; thyroid cancer; therapy advanced; therapy ... See more keywords
Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
Sign Up to like & getrecommendations! Published in 2021 at "OncoTargets and therapy"
DOI: 10.2147/ott.s272208
Abstract: Abstract Cholangiocarcinoma is one of the most aggressive cancers, with a 5-year survival rate of 11–44% after surgical resection. However, there is no established systemic therapy after failure of the gemcitabine plus cisplatin first-line therapy… read more here.
Keywords: cholangiocarcinoma; therapy advanced; genomic aberrations; advanced cholangiocarcinoma ... See more keywords